Biomet is now Zimmer Biomet


Contenu du message

Ce site web peut faire apparaître un ou plusieurs cookies sur votre ordinateur. Pour plus d’informations sur les cookies en général, et les plus spécifiques qui peuvent apparaître sur ce site web, veuillez lire notre politique sur les cookies. Pour plus d’informations sur la gestion des cookies, y compris sur la manière de les empêcher d’apparaître sur votre écran de façon permanente, visitez notre site web Tout sur les cookies. L’utilisation continue du site web Biomet peut être perçue comme un consentement de votre part pour nous permettre de configurer un ou plusieurs cookies sur votre ordinateur.


Switzerland (French) Changement

Information pour professionnel du corps medical

Avantage Cemented Cup


  • Cemented dual mobility cup
  • Indicated for primary, revision and fracture in the treatment of patients at risk of instability
  • Can also be combined with a reinforcement ring or a construct cage
  • Paprosky grade 1 to 2A









Avantage Acetabular Avantage


Leading European national hip registries report that 12 to 16% of revision hip surgeries are due to dislocation1-3. This issue affects between 12,000 and 22,000 patients annually and therefore generates an estimated cost to healthcare providers of €58M to €78M each year4

Avantage is a Dual Mobility Acetabular System introduced by Biomet in 1998, to address patients with high risk of dislocation. Since 2005, the Avantage system has been the N°1 cementless and cemented dual mobility cup on the market5.



Key Features:


Dual Mobility Concept:

  • High range of motion
  • Low risk of dislocation
  • Low risk of PE wear
  • High long term stability


Proprietary Shell Design:

  • Superior Cap helps reduce risk of superior dislocation
  • Anatomic aperture helps reduce risk of impingement and increases ROM
  • Flattened pole helps increase peripheral load
  • Smooth superior-inferior transition helps reduce soft tissue irritation


E1 Antioxidant Infused Technology

  • Maximized strength6,7
  • Maximized wear resistance8
  • Prevention of oxidation7


Clinical Success:

  • 96.9% survival rate @ 9 years, National Joint Registry - England, Wales and NI9
  • 96.3% survival rate @ mean 7.2 years, Fresard et al, Multicentre Study10
  • 0.36% dislocation rate11
  • 7B ODEP rating



1. Swedish Hip Arthroplasty Registry (2012)

2. National Joint Registry for England Wales and Northern Island, 10th Annual Report, 2013

3. Danish Hip Arthroplasty Register, Annual Report, 2011

4. Biomet Market Analysis  - see appendix  for workings and references.

5. Eucomed data reports. Period: 2005-2013

6. Data on file at Biomet: Report “E1 tapered liner Rim Impingement test” Instituto de Biomecánica de Valencia

7. Data on file at Biomet. Bench test results not necessarily indicative of clinical performance.

8. Data on file at Biomet. Wear testing of Avantage E1 liners – Verification and/or validation report number INST: not necessarily indicative of clinical performance.

9. NJR data extract, March 2014 – analysed by Biomet

10. Fresard, PL. et al. Seven-year results of a press-fit, hydroxyapatite-coated double mobility acetabular component in patients aged 65 years or older. European Journal of Orthopeadic Surgery and Traumatology. 23:425–429, 2013.

11. Mukka, S. et al. Dual Mobility Cups for Preventing Early Hip Arthroplasty Dislocation in Patients at Risk: Experience in a County Hospital. Orthopedic Reviews (Pavia). 5(2): e10, 2013.

All content herein is protected by copyright, trademarks and other intellectual property rights owned by or licensed to Biomet Inc. or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Biomet.    

This material is intended for health care professionals and the Biomet sales force only. Distribution to any other recipient is forbidden.